Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Cash & Equivalents (2022 - 2025)

Historic Cash & Equivalents for Addex Therapeutics (ADXN) over the last 4 years, with Q3 2025 value amounting to $2.7 million.

  • Addex Therapeutics' Cash & Equivalents fell 2927.02% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 2927.02%. This contributed to the annual value of $3.8 million for FY2024, which is 1174.34% down from last year.
  • As of Q3 2025, Addex Therapeutics' Cash & Equivalents stood at $2.7 million, which was down 2927.02% from $2.8 million recorded in Q2 2025.
  • In the past 5 years, Addex Therapeutics' Cash & Equivalents registered a high of $22.2 million during Q1 2022, and its lowest value of $3.72 during Q1 2025.
  • In the last 4 years, Addex Therapeutics' Cash & Equivalents had a median value of $3.9 million in 2024 and averaged $6.7 million.
  • In the last 5 years, Addex Therapeutics' Cash & Equivalents tumbled by 10000.0% in 2023 and then soared by 5524285183.99% in 2024.
  • Addex Therapeutics' Cash & Equivalents (Quarter) stood at $7.2 million in 2022, then crashed by 39.66% to $4.4 million in 2023, then fell by 12.46% to $3.8 million in 2024, then fell by 28.32% to $2.7 million in 2025.
  • Its Cash & Equivalents stands at $2.7 million for Q3 2025, versus $2.8 million for Q2 2025 and $3.72 for Q1 2025.